91 completed, 40 terminated, 6 withdrawn, 5 active not recruiting. 56 Phase 2, 33 Phase 3, 27 Phase 1, 18 Phase 4, 5 Not applicable.
Follow EMD Serono: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY) OCP pause - Fertility Preservation | Not applicable | Recruiting | Shady Grove Fertility Reproductive Science Center | 394 | 2026-02-25 | 2026-03-02 |
| Avelumab and M1774 in ARID1A-mutated Endometrial Cancer Avelumab, M1774 - Endometrial Cancer, ARID1A Gene Mutation | Phase 2 | Active not recruiting | Panagiotis Konstantinopoulos, MD, PhD | 8 | 2024-11-14 | 2026-10-26 |
| Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments Geriatric-8 Survey, National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18), Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) - Bladder Cancer, Metastatic Bladder Cancer | Recruiting | Dana-Farber Cancer Institute | 180 | 2024-03-05 | 2026-02-17 | |
| FSH and LH Versus FSH Alone for Ovarian Stimulation in Non-hormone Sensitive Onco-fertility Patients Luveris - Fertility Preservation | Phase 3 | Not yet recruiting | Ellen Greenblatt | 140 | 2024-02-01 | 2024-01-29 |
| Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer Xevinapant, Carboplatin, Paclitaxel - Head and Neck Cancer, Head and Neck Neoplasms | Phase 1 | Terminated | University of Chicago | 42 | 2024-01-24 | 2026-03-31 |
| Patient-Centered Care Survey Infertility | Completed | Inception Fertility Research Institute, LLC | 1500 | 2023-10-23 | 2024-08-22 | |
| Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study Multiple Sclerosis | Completed | University of Colorado, Denver | 76 | 2021-05-18 | 2024-09-25 | |
| Aerobic Exercise for Remyelination in Multiple Sclerosis Aerobic exercise, Education Group Control - Multiple Sclerosis, Sclerosis | Not applicable | Completed | Oregon Health and Science University | 60 | 2021-04-29 | 2026-09-23 |
| Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma Avelumab, Comprehensive Ablative Radiation Therapy - Merkel Cell Carcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 18 | 2021-03-08 | 2026-04-07 |
| A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets Cladribine Tablets - Multiple Sclerosis | Phase 4 | Unknown | Keith Edwards, M.D. | 30 | 2020-09-16 | 2022-01-13 |
| Cladribine Tablets After Treatment With Natalizumab (CLADRINA) Cladribine - Multiple Sclerosis | Phase 4 | Active not recruiting | University of Texas Southwestern Medical Center | 40 | 2020-02-19 | 2025-12-08 |
| Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma Avelumab, AVB-S6-500 - Urothelial Carcinoma | Phase 1 | Active not recruiting | University of Oklahoma | 19 | 2020-02-17 | 2026-03-13 |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors avelumab, Bempegaldesleukin, talazoparib - Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Terminated | Pfizer | 3 | 2019-12-30 | 2021-10-14 |
| Validation of a Shared Decision-Making Tool for Multiple Sclerosis MS-SUPPORT - Multiple Sclerosis | Not applicable | Completed | Shared Decision Making Resources | 501 | 2019-11-12 | 2022-05-09 |
| Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis Cladribine - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Completed | Gregory Wu | 47 | 2019-10-28 | 2026-07-28 |
| Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer Avelumab, BCG - Bladder Cancer | Phase 1 / Phase 2 | Completed | University of Oklahoma | 18 | 2019-05-01 | 2024-02-14 |
| The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy Avelumab and Radical radiotherapy - Squamous Cell Carcinoma of the Skin | Phase 2 | Terminated | AHS Cancer Control Alberta | 8 | 2019-04-12 | 2025-06-27 |
| Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC Avelumab, 2nd generation ADT (abiraterone or enzalutamide) - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Terminated | Jodi Layton, MD | 8 | 2019-01-25 | 2024-07-09 |
| Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Oxaliplatin, Leucovorin, 5 fluorouracil - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Completed | Ashwin Somasundaram | 18 | 2019-01-24 | 2023-12-19 |
| M6620 (VX-970) in Selected Solid Tumors M6620 - Solid Tumor, Leiomyosarcoma | Phase 2 | Completed | Massachusetts General Hospital | 30 | 2019-01-08 | 2023-07-07 |
Showing 20 of 146. Sign in to see all of them.
Multiple Sclerosis (25) · Infertility (14) · Carcinoma, Non-Small-Cell Lung (11) · Multiple Sclerosis, Relapsing-Remitting (11) · Neoplasm Metastasis (7) · Dwarfism, Pituitary (6) · Glioblastoma (5) · Recurrence (5) · Urinary Bladder Neoplasms (5) · Colorectal Neoplasms (4) · Lupus Erythematosus, Systemic (4) · Melanoma (4) · Neoplasms (4) · Ovarian Neoplasms (4) · Autoimmune Diseases of the Nervous System (3)
avelumab (19) · Human Growth Hormone (13) · Interferon beta-1a (12) · TACI receptor-IgG Fc fragment fusion protein (11) · Growth Hormone (10) · N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide (7) · Radiotherapy (5) · Cilengitide (4) · Cladribine (4) · Cyclophosphamide (4) · L-BLP25 (4) · Luteinizing Hormone, beta Subunit (4) · Chorionic Gonadotropin (3) · Gemcitabine (3) · IMO-2055 (3)
United States (117) · Germany (27) · Canada (21) · Spain (20) · Belgium (16) · United Kingdom (16) · Italy (15) · France (14) · Czechia (13) · Poland (13) · Russia (13) · Switzerland (12) · Australia (11) · Netherlands (8) · South Africa (8)
Fernando Dangond, MD (5) · Andriy Markivskyy, MD (2) · Claudia Pena Rossi, M.D. (2) · Claudio Benadiva, MD, HCLD (2) · Eduardo Kelly, MD, MBA (2) · Elisabetta Verdun di Cantogno, MD (2) · Phil Breitfeld, MD (2) · Aaron L Boster, MD (1) · Abhishek Tripathi, MD (1) · Alice Domar, PhD (1) · Annick Delvigne, PhD (1) · Anthony Priestley, MBChB MFPM (1)
PMID 24613349, PMID 32447743, PMID 36346112, PMID 37332136, PMID 15076238, PMID 16193898, PMID 16831964, PMID 17022858, PMID 17126894, PMID 17654600, PMID 17692727, PMID 18175337, PMID 18292808, PMID 18292816, PMID 18755819, PMID 18789766, PMID 18981465, PMID 19145731, PMID 19302707, PMID 20089960, PMID 20347079, PMID 20433746, PMID 20718590, PMID 20961422, PMID 20978446, PMID 21452293, PMID 21452294, PMID 22017519, PMID 22325903, PMID 23216674, PMID 23320927, PMID 23414459, PMID 23746966, PMID 23832397, PMID 24331154, PMID 24625687, PMID 24668327, PMID 24894651, PMID 24951103, PMID 24976972, PMID 25163906, PMID 25558798, PMID 25627002, PMID 25722382, PMID 26559139, PMID 28140753, PMID 28173814, PMID 28194539, PMID 28255849, PMID 28289865
2009 (3), P30CA015704 (2), 2008 (1), 2016 (1), 2019 (1), K23HD101667 (1), K24CA139052 (1), R01AI043864 (1), R01CA032685 (1), R01CA176841 (1), UL1TR002369 (1)